Trials / Completed
CompletedNCT06145178
A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants
A Phase I First in Human Study to Assess Safety and Immunogenicity of the Human Cytomegalovirus Vaccine Candidate SPYVLP01 With and Without Adjuvants in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- SpyBiotech Limited · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of the study is to evaluate the safety and immunogenicity of SPYVLP01 in two different doses with and without adjuvants in healthy adults aged 18-50 years old.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SPYVAC01 | Novel vaccine SPYVLP01 |
Timeline
- Start date
- 2023-11-22
- Primary completion
- 2025-06-20
- Completion
- 2025-07-09
- First posted
- 2023-11-24
- Last updated
- 2025-09-22
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT06145178. Inclusion in this directory is not an endorsement.